EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Microfluidic electroporation for drug and gene delivery: Driving innovation from single-cell precision to high-throughput preclinical and therapeutic platforms

Cher J S Liu, Shao-Bo Wang, Pin-Yu Su, Yuan-Pang Hsieh, Hsiang-Yu Wang

Advanced Drug Delivery Reviews · 2026

DOI: 10.1016/j.addr.2026.115851 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026. Verfasst von Cher J S Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Engineering and System Science, National Tsing Hua University, Taiwan. Hauptthemen laut MEDLINE: Electroporation, Gene Transfer Techniques, Microfluidics, Drug Delivery Systems. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 351 Literaturangaben. Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intracellular delivery of therapeutic biomolecules represents a fundamental prerequisite for cell-based therapies and precision medicine, yet existing delivery methods present critical limitations. Viral vectors, while effective, pose safety risks including immunogenicity and insertional mutagenesis. Bulk electroporation offers a non-viral alternative but suffers from high cytotoxicity, heterogeneous electric field distributions, and poor efficiency in primary cells due to excessive voltage requirements and uncontrolled Joule heating. Microfluidic electroporation exploits microscale physics to decouple transfection efficiency from cell viability. By reducing electrode spacing to micrometers, these platforms achieve necessary field strengths at voltages below 50 V, minimizing Joule heating and electrolysis byproducts that plague bulk methods. Static platforms, including nanostructure-assisted designs, provide subcellular precision through localized field enhancement and real-time impedance monitoring, enabling mechanistic investigation of pore formation dynamics. Continuous-flow systems transform electroporation into a scalable manufacturing process, achieving throughputs of 108-109 cells per minute required for clinical cell therapy production while maintaining viabilities above 90% through hydrodynamic focusing and optimized channel geometries. Despite these engineering advances, systematic benchmarking against Current Good Manufacturing Practice (cGMP)-compliant commercial electroporators reveals critical translational barriers: reliance on research-grade polydimethylsiloxane instead of medical-grade thermoplastics, open manual workflows incompatible with sterile closed-system requirements, lack of validated process control protocols, and insufficient biological verification beyond transient fluorescent protein expression. Furthermore, cargo-specific constraints, including nuclear transport requirements for plasmid DNA versus ribonucleoprotein complexes and distinctions between transient mRNA expression versus permanent CRISPR/Cas9 genomic integration, demand fundamentally different optimization strategies rarely addressed in device-focused studies. Establishing microfluidic electroporation as a viable clinical platform requires integrated manufacturing modules coupling electroporation with upstream buffer exchange and downstream cell sorting, along with implementation of real-time process analytical technology and closed-loop artificial intelligence-driven control. Early regulatory engagement to establish Drug Master File pathways will enable broad therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ElectroporationGene Transfer TechniquesMicrofluidicsDrug Delivery SystemsHumansAnimalsElectroporation Therapies

Stichwörter der Autor:innen

Artificial intelligence-driven process optimizationBiomanufacturingIntracellular deliveryMicrofluidic electroporationNon-viral gene deliveryOrganoids and organs-on-chipsTransfection efficiency

Autor:innen und Institutionen

  • Department of Engineering and System Science, National Tsing Hua University, Taiwan.
  • Department of Chemical Engineering, National Taiwan University of Science and Technology, Taiwan.
  • Department of Chemical Engineering, National Taiwan University of Science and Technology, Taiwan. Electronic address: yphsieh@mail.ntust.edu.tw.
  • Department of Engineering and System Science, National Tsing Hua University, Taiwan; Institute of Nuclear Engineering, National Tsing Hua University, Taiwan; College of Sustainability, National Tsing Hua University, Tai…

Förderung

  • National Science and Technology Council

Zitieren

APA

Liu, C. J. S., Wang, S. B., Su, P. Y., Hsieh, Y. P., & Wang, H. Y. (2026). Microfluidic electroporation for drug and gene delivery: Driving innovation from single-cell precision to high-throughput preclinical and therapeutic platforms. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2026.115851

Vancouver

Liu CJS, Wang SB, Su PY, Hsieh YP, Wang HY. Microfluidic electroporation for drug and gene delivery: Driving innovation from single-cell precision to high-throughput preclinical and therapeutic platforms. Advanced Drug Delivery Reviews. 2026. doi:10.1016/j.addr.2026.115851

BibTeX
@article{Liu2026,
  author = {Liu, Cher J S and Wang, Shao-Bo and Su, Pin-Yu and Hsieh, Yuan-Pang and Wang, Hsiang-Yu},
  title = {Microfluidic electroporation for drug and gene delivery: Driving innovation from single-cell precision to high-throughput preclinical and therapeutic platforms},
  journal = {Advanced Drug Delivery Reviews},
  year = {2026},
  doi = {10.1016/j.addr.2026.115851}
}
Kostenlos starten →